Entrada Therapeutics, Inc. (TRDA) News
Follow Entrada Therapeutics, Inc. (TRDA) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 6 public stories across 4 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
TRDA - Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant Program
TRDA - Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant Program
EQUITY | Sep 10, 2026, 11:00 AM UTC
L
TRDA: Upcoming clinical data and platform safety position the company for accelerated approval and market growth
The EEV platform enables superior delivery and safety for oligonucleotide therapies, with clinical programs in DMD showing early functional benefits and strong safety. Upcoming data from higher-dose cohorts and expansion
EQUITY | Sep 09, 2026, 06:23 PM UTC
M
TRDA touts EEV platform safety and less frequent dosing for DMD
TRDA’s conference update said its EEV platform showed strong safety, enhanced delivery and less frequent dosing for DMD therapies, alongside early functional and biomarker data. It cited upcoming clinical readouts and ro
EQUITY | Sep 09, 2026, 05:59 PM UTC
L
Entrada Therapeutics announces inducement grants under Nasdaq Rule 5635(c)(4)
Entrada Therapeutics, Inc. announced inducement grants under Nasdaq Listing Rule 5635(c)(4).
EQUITY | Sep 02, 2026, 08:51 PM UTC
L
TRDA announces inducement grants under Nasdaq Rule 5635(c)(4)
Entrada Therapeutics (TRDA) announced inducement grants under Nasdaq listing rule 5635(c)(4).
EQUITY | Sep 02, 2026, 08:30 PM UTC
L
TRDA - Entrada Therapeutics Reports Second Quarter 2026 Financial Results
TRDA - Entrada Therapeutics Reports Second Quarter 2026 Financial Results
EARNINGS | Aug 05, 2026, 11:01 AM UTC